Cerus (CERS) reported $234M in revenue for fiscal 2025, +16.1% year on year. That ranks #2610 by revenue among 2853 SEC filers and #273 in Healthcare. It posted a net loss of −$15.6M for the same year. Revenue has grown 15.0% a year on average since 2011 ($33.0M then). The fiscal 2025 balance sheet shows $222M in total assets, $20.0M in cash and $20.0M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $234M | +16.1% | FY20252025-12-31 |
| Gross profitGrossProfit | $16.9M | +57.0% | FY20162016-12-31 |
| Operating incomeOperatingIncomeLoss | −$8.7M | +$5.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$15.6M | +$5.3M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $4.8M | −57.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.7M | +31.4% | FY20252025-12-31 |
| Total assetsAssets | $222M | +10.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $64.2M | +14.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $20.0M | −1.5% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $20.0M | +100.0% | FY20152015-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $53.7M | −$1.6M | Open → |
| Q2 20262026-06-30 | $57.4M | −$2.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Cerus Corp
- Ticker
- CERS
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001020214
Filings
- 10-QJul 30, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KMar 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| OrthopediatricsKIDS | $236M | −$39.6M |
| Akebia TherapeuticsAKBA | $236M | −$5.3M |
| AnaptysbioANAB | $235M | −$13.2M |
| CerusCERS | $234M | −$15.6M |
| TalkspaceTALK | $229M | $7.8M |
| LifevantageLFVN | $229M | $9.8M |
| Puma BiotechnologyPBYI | $228M | $31.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Cerus — Key figures |url=https://companiesranked.com/en/company/cerus |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Cerus — Key figures. CompaniesRanked. https://companiesranked.com/en/company/cerusBibTeX
@misc{companiesranked-en-company-cerus-2026,
author = {{CompaniesRanked}},
title = {{Cerus — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/cerus}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-085678 · March 2, 2026
{{cite web |title=Cerus — Key figures — 10-K (0001193125-26-085678) |url=https://www.sec.gov/Archives/edgar/data/1020214/000119312526085678/cers-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.